Department of Physiology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada.
EBioMedicine. 2019 Apr;42:203-213. doi: 10.1016/j.ebiom.2019.03.008. Epub 2019 Mar 14.
Gabapentin is a structural analog of the inhibitory neurotransmitter γ-aminobutyric acid (GABA). Its anticonvulsant, analgesic and anxiolytic properties suggest that it increases GABAergic inhibition; however, the molecular basis for these effects is unknown as gabapentin does not directly modify GABA type A (GABA) receptor function, nor does it modify synaptic inhibition. Here, we postulated that gabapentin increases expression of δ subunit-containing GABA (δGABA) receptors that generate a tonic inhibitory conductance in multiple brain regions including the cerebellum and hippocampus.
Cell-surface biotinylation, Western blotting, electrophysiologic recordings, behavioral assays, high-performance liquid chromatography and gas chromatography-mass spectrometry studies were performed using mouse models.
Gabapentin enhanced expression of δGABA receptors and increased a tonic inhibitory conductance in neurons. This increased expression likely contributes to GABAergic effects as gabapentin caused ataxia and anxiolysis in wild-type mice but not δ subunit null-mutant mice. In contrast, the antinociceptive properties of gabapentin were observed in both genotypes. Levels of GABA receptor agonists and neurosteroids in the brain were not altered by gabapentin.
These results provide compelling evidence to account for the GABAergic properties of gabapentin. Since reduced expression of δGABA receptor occurs in several disorders, gabapentin may have much broader therapeutic applications than is currently recognized. FUND: Supported by a Foundation Grant (FDN-154312) from the Canadian Institutes of Health Research (to B.A.O.); a NSERC Discovery Grant (RGPIN-2016-05538), a Canada Research Chair in Sensory Plasticity and Reconsolidation, and funding from the University of Toronto Centre for the Study of Pain (to R.P.B.).
加巴喷丁是抑制性神经递质 γ-氨基丁酸(GABA)的结构类似物。其抗惊厥、镇痛和抗焦虑特性表明它增加 GABA 能抑制;然而,这些作用的分子基础尚不清楚,因为加巴喷丁不会直接改变 GABA A 型(GABA)受体功能,也不会改变突触抑制。在这里,我们假设加巴喷丁增加了δ亚基包含的 GABA(δGABA)受体的表达,该受体在包括小脑和海马在内的多个脑区产生紧张性抑制电流。
使用小鼠模型进行细胞表面生物素化、Western blot、电生理记录、行为测定、高效液相色谱和气相色谱-质谱研究。
加巴喷丁增强了 δGABA 受体的表达,并增加了神经元的紧张性抑制电流。这种表达的增加可能有助于 GABA 能作用,因为加巴喷丁在野生型小鼠中引起共济失调和焦虑缓解,但在 δ 亚基缺失突变小鼠中则没有。相比之下,加巴喷丁的抗伤害感受特性在两种基因型中都观察到。加巴喷丁并未改变大脑中 GABA 受体激动剂和神经甾体的水平。
这些结果提供了令人信服的证据来解释加巴喷丁的 GABA 能特性。由于几种疾病中 δGABA 受体表达减少,加巴喷丁可能具有比目前认识更广泛的治疗应用。资金:由加拿大卫生研究院(FDN-154312)基金会资助(B.A.O.);由自然科学与工程研究理事会发现资助(RGPIN-2016-05538)、加拿大知觉可塑性和再巩固研究主席和多伦多大学疼痛研究中心资助(R.P.B.)。